[1] 高红艳,刘娜,李春霞,等.慢性乙型肝炎病毒感染者免疫耐受期的临床特征与肝组织病理学分析.肝脏,2018,23:136-139.
[2] Yan Z, Qiao B, Zhang H, et al. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. Medicine (Baltimore),2018,97:e11716.
[3] 张志.黑色素瘤缺乏因子2在肿瘤发生发展中的研究进展.医学研究生学报,2017,30: 542-545.
[4] 刘颖婷.AIM2在结直肠癌中的作用机制及对免疫治疗的意义.中国肿瘤生物治疗杂志,2018,25:300-304.
[5] Du W, Zhen J, Zheng Z, et al. Expression of AIM2 is high and correlated with inflammation in hepatitis B virus associated glomerulonephritis. J Inflamm (Lond),2013,10:37. .
[6] 张国山,王芳,安爽,等.乙型肝炎病毒相关性肾炎的研究进展.中国老年学杂志,2015,30:1130-1133.
[7] 陈洪涛,陈月,吴诗品,等.NLRP3、AIM2、IFI16炎症小体在慢性乙型病毒性肝炎患者PBMC中的活化水平和与HBV感染的相关性分析.暨南大学学报(自然科学与医学版),2017,38:322-329.
[8] Tashiro M, Sasatomi Y, Watanabe R, et al. IL-1β promotes tubulointerstitial injury in MPO-ANCA-associated glomerulonephritis. Clin Nephrol,2016,86:190-199.
[9] Zhen J, Zhang L, Pan J, et al. AIM2 mediates inflammation-associated renal damage in hepatitis B virus-associated glomerulonephritis by regulating caspase-1, IL-1β, and IL-18. Media Inflamm,2014,2014:190860.
[10] 郝立肖.AIM2在肿瘤中的研究进展.实用肿瘤学杂志,2017,31:175-178.
[11] 黄劲,庞秀青,谢冬英,等.DNA识别受体在乙型肝炎发病机制中的作用.临床肝胆病杂志,2017,33:1794-1797.
[12] 黄劲,莫志硕,庞秀青,等.DNA识别受体AIM2和cGAS相关的HBV感染体外模型建立.热带医学杂志,2018,18:440-444. |
